人工智能遇上肿瘤学：Caris Life Sciences的53.5亿美元IPO考验投资者对精准医疗的兴趣-动脉网

AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine

benzinga 等信源发布 2025-06-17 21:01



可切换为仅中文







Caris Life Sciences

卡里斯生命科学公司

, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.

，一家人工智能驱动的精准肿瘤学公司，计划在美国首次公开募股中以53.5亿美元的估值筹集高达4.235亿美元的资金。

The Irving, Texas-based firm, backed by investment giants

总部位于德克萨斯州欧文市的公司，受到投资巨头的支持

Sixth Street

第六街

and

和

Neuberger Berman

路博迈集团

, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc

，已经对84.9万个患者案例进行了650万次分子测试，并与包括Moderna Inc在内的100多家生物制药公司建立了合作伙伴关系。

MRNA

信使核糖核酸

and AbbVie

和艾伯维

ABBV

, according to its

，根据其

prospectus

招股说明书

filed with the U.S. Securities and Exchange Commission.

向美国证券交易委员会提交。

Don't Miss:

不要错过：

Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —

售价6万美元的可折叠房屋制造商拥有3座厂房、建造了600多套房屋，并且有宏大的计划来解决住房问题——

this is your last chance to become an investor for $0.80 per share.

这是您以每股 0.80 美元成为投资者的最后机会。

Inspired by Uber and Airbnb – Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets –

受Uber和Airbnb的启发——德勤增长最快的软件公司正在将70亿部智能手机转化为产生收入的资产——

with $1,000 you can invest at just $0.30/share!

用1000美元，你只需每股0.30美元就可以投资！

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

上市前优惠：以每股仅0.80美元的价格成为BOXABL的早期股东，抓住近5万亿美元的全球机遇。

Massive Demand & Disruptive Potential

巨大需求与颠覆性潜力

– Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.

– Boxabl已经收到了超过19万套房屋的意向，将自己定位为住房市场的主要颠覆者。

Revolutionary Manufacturing Approach

革命性的制造方法

– Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.

– 受亨利·福特装配线的启发，Boxabl的可折叠小型住宅旨在实现高效率生产，使拥有住房变得更加可行。

Affordable Investment Opportunity

低成本投资机会

– With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.

– 由于房屋售价为60,000美元，Boxabl正在筹集10亿美元以扩大生产规模，为投资者提供了一个参与其增长的机会。

Share Price

股价

：

$0.80

0.80美元

Min. Investment

最低投资金额

：

$1,000

1000美元

Valuation

估值

：

$3.5B

35亿美元

Click Here To Invest For Just $0.80/Share ($1000 Min)

点击此处以每股仅0.80美元的价格投资（最低1000美元）

Valuation Context and Financial Performance

估值背景与财务绩效

The $5.35 billion target—based on 23.5 million shares priced between $16 and $18 each—marks a notable shift from Caris' 2021 private valuation of $7.83 billion, Reuters reported, reflecting both market recalibration and the challenges of commercializing precision medicine.

基于每股16至18美元的2350万股，53.5亿美元的目标标志着Caris在2021年78.3亿美元的私人估值发生了显著变化，路透社报道，这反映出市场重新调整以及将精准医疗商业化的挑战。

According to its filing, Caris generated $412.3 million in revenue in 2024—a 35% year-over-year increase—while posting a net loss of $257.1 million. In Q1 2025, the company reported $120.9 million in revenue and a narrowed net loss of $127 million, compared to $80.7 million in revenue and a $134.1 million loss during the same period in 2024, according to its filing—signaling improving margins and sustained top-line growth..

根据其文件披露，Caris在2024年实现了4.123亿美元的收入，同比增长35%，同时净亏损为2.571亿美元。文件还显示，2025年第一季度，公司报告收入为1.209亿美元，净亏损收窄至1.27亿美元，而2024年同期收入为8070万美元，亏损1.341亿美元，这表明其利润率正在改善，且收入持续增长。

At its proposed valuation, Caris would trade at approximately 13 times sales, a premium to peers like Guardant Health

按其预期估值，Caris的市销率约为13倍，较Guardant Health等同行存在溢价。

and Tempus AI

和Tempus AI

TEM

透射电子显微镜

, Reuters reported.

，路透社报道。

Trending: Invest where it hurts — and help millions heal:

趋势：投资于痛苦之处——并帮助数百万人治愈：

Invest in Cytonics and help disrupt a $390B Big Pharma stronghold

投资Cytonics，帮助打破一个3900亿美元的大型制药巨头的垄断。

。

Technology and Competitive Edge

技术与竞争优势

According to the company's website, Caris was founded in 2008 by entrepreneur David D. Halbert, who was inspired by his father's cancer battle to develop more effective, data-driven diagnostics. Today, the company operates from its North Texas headquarters and has offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland, serving both U.S.

根据该公司网站的信息，Caris 由企业家 David D. Halbert 于2008年创立，他受到父亲抗癌经历的启发，致力于开发更有效、数据驱动的诊断技术。如今，公司总部位于北德克萨斯，并在凤凰城、纽约、马萨诸塞州剑桥、日本东京和瑞士巴塞尔设有办事处，服务于美国及其他地区。

and international markets..

以及国际市场。

Caris' proprietary AI platform, which integrates molecular science with machine learning, analyzes comprehensive genomic, transcriptomic, and proteomic data to guide cancer treatment. The company holds 27 issued patents along with over 170 applications pending worldwide, according to its website. Its flagship MI Cancer Seek test, cleared by the U.S.

卡里斯 proprietary AI平台整合了分子科学与机器学习，分析全面的基因组、转录组和蛋白质组数据以指导癌症治疗。据其官网介绍，该公司拥有27项已颁发的专利以及全球范围内超过170项正在申请中的专利。其旗舰产品MI Cancer Seek测试已获得美国食品药品监督管理局的批准。

Food and Drug Administration in 2023, detects early-stage malignancies with what the company claims is unmatched accuracy, the .

美国食品药品监督管理局在 2023 年推出，可检测早期恶性肿瘤，该公司声称其准确性无与伦比。

company

公司

said at the time.

当时说。

Investor Sentiment and Sector Implications

投资者情绪与行业影响

Caris will trade on the Nasdaq under the symbol CAI The offering is led by BofA Securities, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets.

Caris 将在纳斯达克上市，股票代码为 CAI。此次发行由美银证券、摩根大通证券有限责任公司、高盛有限责任公司和花旗环球金融牵头。

Grand View Research

大视野研究

projects a 22.5% CAGR in the AI cancer diagnostics market through 2030, highlighting strong growth potential in this sector.

预计到2030年，人工智能癌症诊断市场将以22.5%的复合年增长率增长，突显了该领域的强劲增长潜力。

See Also: Maximize saving for your retirement and cut down on taxes:

另请参阅：最大化退休储蓄并减少税收：

Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation

预约与财务顾问的免费通话，开启您的财务之旅——无费用，无义务。

Neuberger Berman has indicated it may purchase up to $75 million worth of shares in the IPO—signaling insider confidence in the company's long-term potential, according to Reuters.

据路透社报道，Neuberger Berman表示可能在首次公开募股中购买价值高达7500万美元的股票，这显示了内部人士对公司长期潜力的信心。

Regulatory and Market Risks

监管和市场风险

Caris Life Sciences currently has one FDA-cleared diagnostic test, MI Cancer Seek, according to its filing.

根据其文件，Caris Life Sciences目前拥有一项FDA批准的诊断测试MI Cancer Seek。

Caris' pipeline includes investigational tools like FOLFIRSTai, an AI-based test for predicting chemotherapy response in metastatic colorectal cancer. While clinically validated, it remains unapproved by the FDA, according to the SEC filing, and stricter regulations could delay its commercialization..

Caris的管线包括像FOLFIRSTai这样的研究性工具，这是一种基于人工智能、用于预测转移性结直肠癌化疗反应的测试。根据SEC文件，尽管该工具已通过临床验证，但仍未获得FDA批准，且更严格的法规可能会延缓其商业化进程。

Conclusion: A Litmus Test for AI Biotech

结论：AI生物技术的试金石

Caris's proposed IPO is drawing attention as a potential marker for the viability of AI-driven healthcare, with Reuters noting the offering comes amid renewed interest in precision diagnostics.

Caris拟议的首次公开募股（IPO）正引起关注，作为人工智能驱动的医疗保健可行性的潜在标志，路透社指出，此次发行正值市场对精准诊断重新燃起兴趣之际。